CAR-T cell therapy is indeed an exciting and promising treatment for multiple myeloma. Here are some key points from the knowledge base:

- What is CAR-T Cell Therapy
- CAR-T cell therapy is a type of immunotherapy that helps the body’s immune system fight cancer more effectively.
- It involves genetically engineering Show Full Answer

CAR-T cell therapy is indeed an exciting and promising treatment for multiple myeloma. Here are some key points from the knowledge base:

- What is CAR-T Cell Therapy?
- CAR-T cell therapy is a type of immunotherapy that helps the body’s immune system fight cancer more effectively.
- It involves genetically engineering T cells to recognize and kill cancer cells.

- Process of CAR-T Cell Therapy:
1. Collecting T Cells:
- T cells are collected from the person with myeloma using a process called apheresis.
2. Genetically Engineering T Cells:
- In the lab, T cells are modified using a virus to insert new DNA, creating CARs (Chimeric Antigen Receptors) on their surface.
3. Growing and Multiplying T Cells:
- The modified T cells are grown and multiplied in the lab, which can take up to three weeks.
4. Returning T Cells to the Body:
- The CAR-T cells are infused back into the patient through an IV after a round of chemotherapy (lymphodepletion) to make room for the new cells.

- Benefits and Risks:
- CAR-T cell therapy can reduce or eliminate signs and symptoms of myeloma, even when other treatments have failed.
- It can cause potentially serious side effects, so patients often stay in the hospital for several weeks for monitoring.

- FDA Approval:
- The U.S. FDA approved a specific type of CAR-T cell therapy for multiple myeloma in March 2021.

This therapy represents a significant advancement in treating multiple myeloma, offering hope for improved outcomes.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

CAR-T Cell Therapy for Multiple Myeloma: What Is It? | MyMyelomaTeam

Gene-Based Therapy May Thwart a Tough Blood Cancer | MyMyelomaTeam